Table 1.
Baseline demographic and clinical characteristics
| Anti-VEGF group (n = 23) | DEX group (n = 20) | p valuea | |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 63.6 (9.3) | 62.3 (7.4) | 0.617c |
| Sex, n (%) | |||
| Women | 5 (21.7) | 7 (35.0) | 0.497 |
| Men | 18 (78.3) | 13 (65.0) | |
| Number of IVI*, n (%) | |||
| 1 | 0 (0.0) | 2 (10.0) | < 0.001b |
| 2 | 0 (0.0) | 9 (45.0) | |
| 3 | 0 (0.0) | 9 (45.0) | |
| 5 | 23 (100.0) | 0 (0.0) | |
| Lens status, n (%) | |||
| Phakic | 4 (17.4) | 6 (30.0) | 0.473 |
| Pseudophakic | 19 (82.6) | 14 (70.0) | |
| Preoperative laser, n (%) | |||
| None | 13 (56.5) | 8 (40.0) | 0.478b |
| PRP | 4 (17.4) | 6 (30.0) | |
| Macular grid | 0 (0.0) | 1 (5.0) | |
| Combined** | 6 (26.1) | 5 (25.0) | |
| Presence of IRF, n (%) | |||
| No | 6 (26.1) | 4 (20.0) | 0.728 |
| Yes | 17 (73.9) | 16 (80.0) | |
| Presence of SRF | |||
| No | 22 (95.7) | 16 (80.0) | 0.167 |
| Yes | 1 (4.3) | 4 (20.0) | |
| PDR, n (%) | |||
| Yes | 14 (60.9) | 12 (60.0) | 1.000 |
| No | 9 (39.1) | 8 (40.0) | |
| BCVA*** | |||
| Mean (SD) | 37.7 (25.3) | 35.7 (22.0) | 0.785c |
| CRT | |||
| Mean (SD) | 560.1 (83.7) | 583.6 (129.4) | 0.478c |
VEGF vascular endothelial grow factor, DEX intravitreal dexamethasone implant, SD standard deviation, IVI intravitreal injections, PRP pan retinal photocoagulation, IRF intraretinal fluid, SRF subretinal fluid, PDR proliferative diabetic retinopathy, BCVA best corrected visual acuity, CRT central retinal thickness
*Aflibercept
**PRP + macular grid
***Letters in the Early Treatment Diabetic Retinopathy Study (ETDRS) charts
aFisher exact test
bChi-squared test
cT test